Investigating the role of platelets in autoimmune diseases
ROLE of PLATELETS in the PATHOPHYSIOLOGY of SYSTEMIC LUPUS
This study looks at how activated platelets interact with immune cells in people with autoimmune diseases like lupus and scleroderma to see how these interactions might affect their condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 450 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg, France) |
| Trial ID | NCT06593041 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the interactions between activated platelets and immune cells in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases such as systemic scleroderma, ANCA vasculitis, inflammatory myositis, and Gougerot-Sjögren syndrome. The research focuses on how these interactions may contribute to the pathophysiology of these conditions, particularly in cases of high disease activity. By comparing platelet-immune cell interactions across different autoimmune diseases, the study seeks to enhance understanding of the immune dysregulation associated with SLE and similar disorders.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 to 70 with a confirmed diagnosis of systemic lupus erythematosus or other specified autoimmune diseases.
Not a fit: Patients who do not have any of the specified autoimmune diseases or are unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved therapeutic strategies targeting platelet-immune cell interactions in autoimmune diseases.
How similar studies have performed: While this study explores novel interactions, previous research has indicated that targeting platelet-immune cell interactions may improve symptoms in related conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients between 18 and 70 years of age * Patient affiliated to a health insurance scheme (beneficiary or beneficiary's beneficiary) * Patient able to understand the aims and risks of research * Patient having signed and dated an informed consent form * Patient for whom the diagnosis of at least one of the following pathologies has been confirmed: * Systemic lupus erythematosus meeting ACR/EULAR 20195 classification criteria. * Systemic scleroderma meeting ACR/EULAR 20136 classification criteria. * ANCA vasculitis according to EULAR/ACR 2022.7-9 classification criteria. * Inflammatory myositis according to EULAR/ACR 201710 classification criteria. * Gougerot-Sjögren syndrome according to EULAR/ACR 2016 classification criteria11. * Rheumatoid arthritis according to ACR/EULAR 201012 classification criteria. Exclusion Criteria: * Patient in exclusion period (determined by a previous or current study) * Inability to give patient informed consent (patient in emergency or immediate life-threatening situation) * Patient under court protection * Patient under guardianship or curatorship
Where this trial is running
Strasbourg, France
- Hopitaux Universitaires de Strasbourg - Hopital de Hautepierre - Service de rhumatologie — Strasbourg, France, France (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.